CN105294817A - Novel triterpenoid, preparation method and medical application thereof - Google Patents
Novel triterpenoid, preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105294817A CN105294817A CN201510836820.9A CN201510836820A CN105294817A CN 105294817 A CN105294817 A CN 105294817A CN 201510836820 A CN201510836820 A CN 201510836820A CN 105294817 A CN105294817 A CN 105294817A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- extract
- cell
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel triterpenoid, a preparation method and medical application thereof. The compound is reported for the first time, is a triterpenoid with novel structure, and can be extracted, separated, purified and obtained from the drying overground part of herba artemisiae scopariae. The compound has effect on inducing apoptosis of SACC-M, and the apoptosis rate is increased with the prolongation of the drug action time and the enhancement of the drug level. Moreover, the compound can be used for developing a drug which can treat salivary adenoid cystic carcinoma.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry aerial parts of oriental wormwood, be separated obtain a kind of and there is triterpenoid for the treatment of adenoid cystocarcinoma of salivary gland effect and preparation method thereof.
Background technology
Oriental wormwood is the dry aerial parts of feverfew shore wormwood artemisia (ArtemisiascopariaWaldst.etKit.) or Herba Artemisiae Scopariae (A.CapillarisThunb.).China's most area all has distribution, main product in Anhui, Zhejiang, Jiangsu, Shaanxi, the province such as Shanxi.The habit of gathering spring claims " capillary wormwood ", and the habit of gathering autumn claims " flower oriental wormwood ".Oriental wormwood is bitter, pungent, be slightly cold, and returns spleen, stomach, liver and gall warp, effect of tool clearing heat and promoting diuresis, promoting the function of the gallbladder to alleviate jaundice.
Oriental wormwood contains number of chemical composition, comprises coumarins, flavonoid, chromogen ketone, organic acid, eneyne class, triterpenes, steroid and aldoketones etc.The sixties in 20th century can be traced back to even more early to the research of tonka bean camphor in oriental wormwood.Coumarins composition in oriental wormwood is mainly simple tonka bean camphor and furocoumarin(e).Flavonoid compound in oriental wormwood is mainly glucosides and the aglycon of flavonol.Containing multiple organic phenol acid compounds in oriental wormwood, its Content of Chlorogenic Acid (chlorogenicacid), coffic acid (caffeicacid) etc. have the aspect effects such as obvious cholagogic and antisepsis and anti-inflammation.
Modern pharmacological research shows, oriental wormwood have loose biliary tract expand about flesh, promote choleresis, increase effect such as cholic acid and bilirubin output in bile.Oriental wormwood and prescription thereof are often applied to the liver diseases such as treatment fatty liver, alcoholic liver, viral hepatitis clinically.Research shows, oriental wormwood has protection liver plasma membrane integrity and good permeability, prevents hepatic necrosis, promotes liver cell regeneration and improves liver microcirculation, suppresses glucuronic acid enzymic activity, strengthens the functions such as liver detoxification.Coumarin kind compound in Herba Artemisiae Scopariae has vasodilation, impels vascular endothelial cell to discharge nitrogen protoxide and prostacyclin, reducing blood-fat, the effects such as anticoagulation.Herba Artemisiae Scopariae can reduce mutagenic compound AFB1 micronuclei, chromosome aberration, sister chromatid exchang and transgenation; There is certain restraining effect to the expression of proto-oncogene c-myc, C-fos, V-sis, have blocking effect to the cancer effect that Sodium Nitrite and N methylbenzylamine bring out.Coffic acids in oriental wormwood etc. can increase number of white blood cells, and vegetable-protein wherein has the effect of inducement interferon.Main component 6,7-escoparone in oriental wormwood has significant hypothermal effect to normal mouse temperature, and fresh beer yeast, 2,4-DNP pyrogenicity rat are also had to obvious antipyretic effect, and have obvious analgesic activity.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry aerial parts of oriental wormwood, be separated obtain a kind of there is triterpenoid for the treatment of adenoid cystocarcinoma of salivary gland effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry aerial parts of oriental wormwood are pulverized by (a), extract with 75 ~ 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 75% ethanol elution, 8 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 90:1,65:1,30:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
Further, described alcohol heat reflux extracts the alcohol concn adopted is 80%.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in preparation treatment adenoid cystocarcinoma of salivary gland medicine.
The application of described pharmaceutical composition in preparation treatment adenoid cystocarcinoma of salivary gland medicine.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry aerial parts (8kg) of oriental wormwood are pulverized by (a), (25L × 3 time) are extracted with 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (351g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 75% ethanol elution, 8 column volumes again, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract (133g); C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 90:1 (8 column volumes), the methylene chloride-methanol gradient elution of 65:1 (8 column volumes), 30:1 (6 column volumes), 15:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (31g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 25:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (17g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (31mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z511.3418, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
30h
48o
5, degree of unsaturation is 7.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 500MHz): H-1 (1.74, ddd, J=14.0, 14.0, 3.8), H-1 (1.45, m), H-2 (1.54, m), H-2 (1.49, m), H-3 (3.17, dd, J=11.4, 4.3), H-5 (1.35, dd, J=13.5, 4.1), H-6 (1.88, m), H-6 (1.68, br, t, J=14.7), H-7 (2.94, d, J=6.5), H-11 (1.82, m), H-11 (1.94, m), H-12 (1.46, m), H-12 (1.89, m), H-15 (1.44, m), H-15 (1.16, ddd, J=12.5, 12.5, 5.3), H-16 (1.28, m), H-16 (2.06, m), H-17 (1.58, m), H-18 (0.91, s), H-19 (0.95, s), H-20 (1.34, m), H-21 (0.83, d, J=6.6), H-22 (0.97, m), H-22 (1.32, m), H-23 (1.77, m), H-23 (1.94, m), H-24 (4.96, tt, J=7.1, 1.4), H-26 (1.49, s), H-27 (1.59, s), H-28 (0.93, s), H-29 (0.81, s), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125Hz): 30.1 (CH
2, 1-C), 26.0 (CH
2, 2-C), 77.5 (CH, 3-C), 37.9 (C, 4-C), 41.3 (CH, 5-C), 20.2 (CH
2, 6-C), 53.4 (CH, 7-C), 64.1 (C, 8-C), 85.2 (C, 9-C), 37.1 (C, 10-C), 22.3 (CH
2, 11-C), 33.8 (CH
2, 12-C), 46.3 (C, 13-C), 59.0 (C, 14-C), 19.7 (CH
2, 15-C), 27.1 (CH
2, 16-C), 51.8 (CH, 17-C), 13.3 (CH
3, 18-C), 15.9 (CH
3, 19-C), 34.1 (CH, 20-C), 17.8 (CH
3, 21-C), 35.2 (CH
2, 22-C), 24.3 (CH
2, 23-C), 124.3 (CH, 24-C), 130.5 (C, 25-C), 17.2 (CH
3, 26-C), 25.1 (CH
3, 27-C), 27.7 (CH
3, 28-C), 15.3 (CH
3, 29-C), 176.8 (C, 30-C), carbon atom mark is see Fig. 1.IR spectrum shows this compound and contains hydroxyl (3617cm
-1), gamma lactone (1764cm
-1) and carbonyl (1727cm
-1) group.
1the display of HNMR spectrum is containing seven methyl signals δ H0.91 (H
3-18), 0.95 (H
3-19), 1.49 (H
3-26), 1.59 (H
3-27), 0.93 (H
3-28) and 0.81 (H
3, and a bimodal signal δ H0.83 (H-29)
3-21, d, J=6.6Hz), illustrate that this compound is triterpene compound.
13cNMR and DEPT composes display 30 carbon signals, comprise seven methyl, six methynes (two containing oxygen methyne and an alkene carbon), nine methylene radical and eight quaternary carbons (a lactone carbonyl carbon, two containing oxygen carbon and an alkene carbon).In addition, side chain has 24 (25)-double bonds (δ C130.5,124.3 and δ H4.96, tt, J=7.1,1.4Hz) signal.In HMBC spectrum, H
3-26 and H
3-27 with C-24 and C-25; H
3-21 and C-17, C-20 and C-22; And H-24 and C-22, C-23, H
3-26 and H
3the above-mentioned inference of the relevance verification of-27.In addition, an ester carbonyl group signal [δ C176.8 (C-30)] and two carbon signals [δ C85.2 (C-9) and 59.0 (C-14)] illustrate that this compound exists a gamma lactone structure.In HMBC spectrum, H
3-18 and C-14; H
2-15 and C-30; H
2-11 and C-9; H-11 α and C-8 and H
3-19 with the relevance verification of C-9 the annexation of 30,9-these functional groups.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
Salivary Adenoid Cystic Carcinoma Cell system SACC-M is purchased from Medical College, Shanghai Communication Univ.'s Oral and Maxillofacial Surgery laboratory.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.RPMI-1640 substratum, trypsinase are purchased from SIGMA company of the U.S..Standard foetal calf serum is purchased from Xingtai City Huifeng biotechnology research institute.Annexin-v-FITC/PI test kit is purchased from Beijing Bao Sai Bioisystech Co., Ltd.PBS is purchased from Tianjin recovery fine chemistry industry institute.MTT powder is purchased from Amresco company.Na2EDTA (EDTA) is purchased from Beijing Yili Fine Chemicals Co., Ltd..Penicillin, Streptomycin sulphate are purchased from North China pharmaceutical Co. Ltd.Dimethyl sulfoxide (DMSO) (DMSO) is purchased from Tianjin Standard Science company limited.Giemsa dye liquor is purchased from Zhuhai Bei Suo Technology Co., Ltd..
XYJ type medical treatment clean work station (Purifying Equipment Co., Ltd., Suzhou), BB5060/BB16 CO2gas incubator (Shanghai Heraeus company), CX21 opticmicroscope (Japanese OLYMPUS), XD-10198101 inverted microscope (south of the River company), flow cytometer (BectionDickinsonFacscaLibur), the full-automatic microplate reader of WeLLscanMK3 (Finland LabsystemsDragon), BFX5-320 type low speed centrifuge (Chinese Shanghai Lu Nan scientific instrument related factory), GF-300 type electronic balance (JapanA & DCompany, Limited), 725 type Ultralow Temperature Freezers (FormaScientific.Inc), micro sample adding appliance (EPPENDORF company).
Two, test method
1, cell cultures
1.1 cell recovery
Prepare 37 DEG C of constant water bath box, taken out by the SACC-M cell cryopreservation tube of Liquid nitrogen storage, directly drop into water bath, shake gently, after it melts rapidly, from water tank, take out cryopreservation tube, this step should be fast, should complete within 30-60 second.Afterwards to open cryopreservation tube after the 75% alcohol wipe sterilization mouth of pipe, by the sucking-off of pipe inner cell suspension, instillation 50mL centrifuge tube also drips more than the 10 times RPMI-1640 nutrient solutions containing 10% serum in centrifuge tube, blow and beat gently, become cell suspension, low-speed centrifugal (1000 revs/min) is after 5 minutes, suck supernatant liquor, wash once with the RPMI-1640 nutrient solution of 10% again, and recentrifuge, after sucking supernatant liquor, with the RPMI-1640 nutrient solution containing 10% foetal calf serum, cell dilution is become cell suspension, be inoculated in 50mL culturing bottle, unscrew bottle cap gently, then CO is put into
2cultivate in incubator, second day changes a nutrient solution, changes nutrient solution afterwards after nutrient solution color is by light red flavescence, when observation of cell climbs 80% of full bottle diapire, carries out passage.
1.2 passage
First after using elbow straw to draw original fluid, repeatedly blow and beat at the bottom of bottle, remove old nutrient solution in bottle afterwards, mixture slaking liquid (0.25% trypsinase and 0.04%EDTA1:1) a small amount of (being advisable covering completely at the bottom of culturing bottle) is added in bottle, at the bottom of slow shake body makes Digestive system soak bottle, then suck most of Digestive system, only stay and digest on a small quantity.Culturing bottle is placed in CO
2in incubator, (or under 25 DEG C of room temperatures) digest, and take out culturing bottle, fell and put basis of microscopic observation after 2 ~ 5 minutes, when discovery kytoplasm retraction, intercellular substance increase, part cell becomes circle from polygon, and when existing cell starts to suspend, should stop digestion immediately.The Digestive system that sucking-off is remaining, adds the appropriate nutrient solution not containing serum, rotates culturing bottle gently, after washing out residual Digestive system, by its sucking-off, then add new nutrient solution, repeatedly blows and beats at the bottom of bottle, make subsides with elbow straw after drawing culture in glassware liquid.Cell detachment at the bottom of bottle, forms cell suspension, and when noting blowing and beating, action wants soft, in case overexert, make cell damage.Drawing cell suspension is placed in centrifuge tube, after centrifugal, removes supernatant, collecting cell, and add the appropriate RPMI-1640 nutrient solution containing 10% foetal calf serum, cell is blown and beaten into suspension, counting, with 1.0 × 10
5/ mL concentration is seeded in new culturing bottle.
2, MTT colorimetric test
(1) inoculating cell: cell in vegetative period of taking the logarithm, making concentration with the RPMI-1640 containing 10% foetal calf serum is 2 × 10
5the single cell suspension of/mL, is inoculated in 96 orifice plates, every hole 100 μ L.(2) culturing cell: above-mentioned 96 orifice plates are placed in CO
2incubator, at 37 DEG C, 5%CO
2and under saturated humidity condition, continue to cultivate 24h.(3) dosing: the every hole of medication group adds compound (I) the liquid 100 μ L after dilution, make its final concentration be 2.5,5.0,7.5,10,12.5mmol/L; The every hole of control group adds 100 μ L not containing the RPMI-1640 of serum.Medication group and control group are often organized and are all established 6 multiple holes, and establish zeroing hole, continue to cultivate after dosing.(4) colour generation: after continuing to cultivate 24h, 48h and 72h, medication group and the every hole of control group add the MTT solution 20 μ L that concentration is 5g/L, after continuing to cultivate 4h, suck whole supernatant liquor, the dimethyl sulfoxide (DMSO) (comprising zeroing hole) of 200 μ L is added in each hole, put vibration on vibrator and shake up 1 minute, crystallization is fully dissolved.(5) colorimetric: be placed in microplate reader by 96 orifice plates is 490nm place at wavelength, measures each hole absorbance (A).Repeat experiment 3 times, get its mean value.(6) calculate and draw: cell proliferation inhibition rate=(1-medication group average A-value/control group average A-value) × 100%.According to the growth inhibition ratio of each concentration of above formulae discovery, be then transverse axis with time, inhibiting rate is the longitudinal axis, draws the inhibiting rate curve of 5 concentration.
3, Flow cytometry
The process of 3.1 cells
After cell inoculation, cultivation, cell in vegetative period of taking the logarithm, with 2 × 10
5/ mL concentration is inoculated in 6 orifice plates, then dosing, if time comparative group, concentrations versus's group and control group (normal apoptotic group): (1) time comparative group: cell is inoculated in 6 orifice plates, cultivate 24 hours, after cell attachment, with suction pipe along each hole wall by thorough for original fluid sucking-off, the final concentration then adding equivalent in each hole is the nutrient solution (medication group) that 12.5mmol/L contains compound (I) liquid.Add not containing compound (I) nutrient solution as a control group, respectively continue cultivate 24h, 48h, 72h.(2) concentrations versus's group: cell inoculation and after adherent success, thoroughly to exhaust original fluid with suction pipe, add respectively in each hole final concentration be 2.5,5.0,7.5,10,12.5mmol/L containing compound (I) nutrient solution (medication group).Control group adds not containing the nutrient solution of compound (I), continues to cultivate 72h.(3) normal apoptotic group: inoculating cell also, after adherent success, removes original fluid in each hole, adds not containing the nutrient solution of compound (I), continues to cultivate 24h, 48h, 72h.
The preparation of 3.2 samples
(1) collecting cell: draw 6 orifice plate each hole supernatant liquors respectively, add in centrifuge tube, after getting each diapire of PBS liquid 2mL rinsing 6 orifice plate, pour in same centrifuge tube, then 2mL mixture slaking drop is entered peptic cell in each hole, slow wave and culture plate makes Digestive system soak its diapire completely, after digestion 2min, Digestive system is sucked each centrifuge tube, add 2mL nutrient solution again and blow and beat each hole diapire, after cell thoroughly takes off wall, suck in centrifuge tube.(2) eccentric cell: centrifuge tube is placed in low speed centrifuge, after the centrifugal 5min of 1500rpm, abandoning supernatant; Add 12mLPBS liquid re-suspended cell, then in the centrifugal 5min of 1500rpm, abandon supernatant liquor; Cell suspension after re-suspended cell, is drawn in the special upper machine pipe of flow cytometer, after the centrifugal 5min of 1500rpm, abandons supernatant liquor by the PBS liquid instilling 3mL again in centrifuge tube.
3.3Annexin-V-FITC and PI double-tagging viable cell method detects apoptosis
(1) in streaming pipe, the Annexin-V-FITC of 10 μ L and the PI (two kinds of reagent do not mix mutually, do not contact with pipe floor cells) of 5 μ L is added with micro sample adding appliance.(2) add 200 μ L binding buffer liquid, Annexin-V-FITC with PI punching is mixed mutually with cell at the bottom of pipe, and blows and beats gently, form single cell suspension.(3) lucifuge is reacted 15min or is put into 4 DEG C of refrigerator 30min.(4) add 300 μ LPBS binding buffer liquid before upper machine, and blow and beat gently, then go up machine (flow cytometer) at once and detect.Light source is 488nm Argon ion laser, and 10000, every part of specimen collection cell, fluoresced green after FITC is stimulated, PI sends out red fluorescence.(5) through flow cytometry analysis, obtain the scatter diagram be made up of four quadrants, on figure, each point represents a cell, all has two parameter values.Upper left Q1 quadrant represents the damaging cells (An-PI+) occurred in cell harvesting process, upper right Q2 quadrant represents non-viable apoptotic cell and non-viable non-apoptotic cell (An+PI+), lower-left Q3 quadrant represents normal cell (An-PI-), and bottom right Q4 quadrant represents viable apoptotic cell (An+PI-).
4, statistical analysis
Using statistics software SPSS10.0 carries out statistical study.(1) use the variance analysis of Factorial Design, compound (I) growth inhibition ratio to SACC-M cell between same medicine concentration different treatment time, each group of same treatment time different pharmaceutical concentration is compared between two.(2) use simple correlation analysis, analyze growth inhibition ratio and the dependency between action time, between inhibiting rate and drug level, draw correlation coefficient r, and t inspection is carried out to r value, thus draw drug effect in time with the variation relation of concentration.(3) each medication group using the u-test flow cytometric art of binominal distribution to detect and the apoptosis rate of control group carry out statistical study.
Three, result and conclusion
1, MTT colorimetric test
(1) experiment shows that compound (I) has obvious inhibited proliferation to SACC-M cell, drug effect 24,48, the highest inhibiting rate can reach 80.4% (table 1) after 72h.(2) inhibiting rate between same treatment time, different concns group compares notable difference (P<0.01); Same concentrations group, inhibiting rate between the different treatment time have notable difference (P<0.01); Drug level and treatment time non-interaction action (P=0.901).(3) compare between two between group: between same time, different concns group, inhibiting rate has notable difference (P<0.01); After process 24h, 48h, 72h, between same concentration, different time group, there is notable difference (P<0.01).(3) drug effect (inhibiting rate) all has positive correlation with action time and drug level, and inhibiting rate and action time have positive correlation (r=0.291, P=0.042); Inhibiting rate and concentration have positive correlation (r=0.926, P<0.001).
2, Flow cytometry
The apoptosis situation of 2.1 cellular control units
Control group (normal apoptotic group) cell all belongs to natural apoptosis, apoptosis rate when its apoptosis rate is 4.9%, 48h during 24h is the apoptosis rate of 7.1%, 72h is 6.1% (table 2), apoptosis rate is little with incubation time difference, not statistically significant.
2.2 medication group cells change apoptosis situation in time
After 12.5mmol/L compound (I) process 24h, its apoptosis rate is 25.5%; After process 48h, apoptosis rate rises to 40.9%, mostly is early apoptosis; After process 72h, apoptosis rate is 67.6%, mostly is late apoptic, and apoptosis rate extends along with the treatment time and obviously rises (table 2), and between each time group, apoptosis rate has statistical significance (P<0.01).
2.3 medication group cells are with change in concentration apoptosis situation
After process 72h, 2.5,5.0 the apoptosis rate that, 7.5,10.0,12.5mmol/L compound (I) is organized is respectively 16%, 24.2%, 26.1%, 66.3%, 67.6%, and when drug level reaches 12.5mmol/L, late apoptic rate obviously increases (table 2), and between each drug level group, apoptosis rate has statistical significance (P<0.01).
Conclusion, this research shows that compound (I) has the effect of induction SACC-M apoptosis, and apoptosis rate with the prolongation of drug treating time and the increase of Drug level in rising trend.Application compound (I) treatment adenoid cystic carcinoma likely becomes the very promising methods for the treatment of of one.
The different inhibiting rate action time (mean value ± SD) of table 1 different concns
Table 2 compound (I) induction SACC-M apoptosis situation
| Concentration-time | Normal cell (%) | Early apoptosis (%) | End-stage apoptotic (%) | Damaging cells (%) |
| 0mmol/L—24h | 93.2 | 0.5 | 4.9 | 1.4 |
| 0mmol/L—48h | 90.4 | 2.3 | 7.1 | 0.3 |
| 0mmol/L—72h | 87.5 | 6.1 | 6.1 | 0.2 |
| 12.5mmol/L—24h | 74.4 | 11.8 | 13.7 | 0.1 |
| 12.5mmol/L—48h | 59 | 35.4 | 5.5 | 0 |
| 12.5mmol/L—72h | 32.4 | 21.3 | 46.3 | 0.1 |
| 2.5mmol/L—72h | 82.4 | 1.5 | 14.5 | 1.7 |
| 5.0mmol/L—72h | 75.7 | 19.3 | 4.9 | 0.1 |
| 7.5mmol/L—72h | 73.9 | 15.2 | 10.9 | 0 |
| 10.0mmol/L—72h | 33.6 | 58.7 | 7.6 | 0.1 |
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry aerial parts of oriental wormwood are pulverized by (a), extract with 75 ~ 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 75% ethanol elution, 8 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 90:1,65:1,30:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
4. the preparation method of compound according to claim 2 (I), is characterized in that: it is 80% that described alcohol heat reflux extracts the alcohol concn adopted.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in preparation treatment adenoid cystocarcinoma of salivary gland medicine.
7. the application of pharmaceutical composition according to claim 5 in preparation treatment adenoid cystocarcinoma of salivary gland medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510836820.9A CN105294817A (en) | 2015-11-25 | 2015-11-25 | Novel triterpenoid, preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510836820.9A CN105294817A (en) | 2015-11-25 | 2015-11-25 | Novel triterpenoid, preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105294817A true CN105294817A (en) | 2016-02-03 |
Family
ID=55192716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510836820.9A Pending CN105294817A (en) | 2015-11-25 | 2015-11-25 | Novel triterpenoid, preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105294817A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105294818A (en) * | 2015-12-07 | 2016-02-03 | 西宁意格知识产权咨询服务有限公司 | New triterpenoid as well as preparation method and medical application thereof |
| CN105541961A (en) * | 2016-03-04 | 2016-05-04 | 宋晓梅 | Withanolide compounds for treating adenoid cystic carcinoma of salivary gland |
| CN106008548A (en) * | 2016-06-02 | 2016-10-12 | 杭州更蓝生物科技有限公司 | New clerodane diterpenoid compound and preparation method thereof |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061197A (en) * | 2015-08-28 | 2015-11-18 | 林天样 | Novel triterpene compound and preparation method and medical application of novel triterpene compound |
| CN105079004A (en) * | 2015-09-16 | 2015-11-25 | 张利文 | Application of salpichrolide R in preparing medicines for treating adenoid cystic carcinoma of salivary gland |
| CN105111275A (en) * | 2015-09-16 | 2015-12-02 | 张利文 | Novel triterpenes, and preparation method and medical application thereof |
| CN105131013A (en) * | 2015-10-18 | 2015-12-09 | 淄博夸克医药技术有限公司 | Novel macrolide compound and preparation method and medical application thereof |
| CN105153269A (en) * | 2015-10-22 | 2015-12-16 | 淄博夸克医药技术有限公司 | New triterpene compounds, and preparation method and medical application thereof |
| CN105218617A (en) * | 2015-09-30 | 2016-01-06 | 宋晓梅 | A kind of new triterpenoid and preparation method thereof and medicinal use |
| CN105294818A (en) * | 2015-12-07 | 2016-02-03 | 西宁意格知识产权咨询服务有限公司 | New triterpenoid as well as preparation method and medical application thereof |
| CN105330717A (en) * | 2015-10-29 | 2016-02-17 | 淄博夸克医药技术有限公司 | Novel triterpenoid and preparation method and medical application thereof |
| CN105418628A (en) * | 2015-12-07 | 2016-03-23 | 西宁意格知识产权咨询服务有限公司 | New kaurane diterpene compound as well as preparation method and application thereof |
| CN105481799A (en) * | 2015-12-29 | 2016-04-13 | 吴金凤 | Highly-oxidized sesquiterpene compound as well as preparation method and medical application thereof |
| CN105503995A (en) * | 2015-12-29 | 2016-04-20 | 吴金凤 | Novel triterpenoid compound as well as preparation method and medical application thereof |
| CN105503899A (en) * | 2016-01-25 | 2016-04-20 | 金华知产婺源信息技术有限公司 | Novel lignan compound and preparation method and medical application thereof |
| CN105503997A (en) * | 2015-12-30 | 2016-04-20 | 吴金凤 | Triterpenoid for treating salivary adenoid cystic carcinoma (SACC) and preparation method thereof |
| CN105541961A (en) * | 2016-03-04 | 2016-05-04 | 宋晓梅 | Withanolide compounds for treating adenoid cystic carcinoma of salivary gland |
-
2015
- 2015-11-25 CN CN201510836820.9A patent/CN105294817A/en active Pending
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105061197A (en) * | 2015-08-28 | 2015-11-18 | 林天样 | Novel triterpene compound and preparation method and medical application of novel triterpene compound |
| CN105079004A (en) * | 2015-09-16 | 2015-11-25 | 张利文 | Application of salpichrolide R in preparing medicines for treating adenoid cystic carcinoma of salivary gland |
| CN105111275A (en) * | 2015-09-16 | 2015-12-02 | 张利文 | Novel triterpenes, and preparation method and medical application thereof |
| CN105218617A (en) * | 2015-09-30 | 2016-01-06 | 宋晓梅 | A kind of new triterpenoid and preparation method thereof and medicinal use |
| CN105131013A (en) * | 2015-10-18 | 2015-12-09 | 淄博夸克医药技术有限公司 | Novel macrolide compound and preparation method and medical application thereof |
| CN105153269A (en) * | 2015-10-22 | 2015-12-16 | 淄博夸克医药技术有限公司 | New triterpene compounds, and preparation method and medical application thereof |
| CN105330717A (en) * | 2015-10-29 | 2016-02-17 | 淄博夸克医药技术有限公司 | Novel triterpenoid and preparation method and medical application thereof |
| CN105294818A (en) * | 2015-12-07 | 2016-02-03 | 西宁意格知识产权咨询服务有限公司 | New triterpenoid as well as preparation method and medical application thereof |
| CN105418628A (en) * | 2015-12-07 | 2016-03-23 | 西宁意格知识产权咨询服务有限公司 | New kaurane diterpene compound as well as preparation method and application thereof |
| CN105481799A (en) * | 2015-12-29 | 2016-04-13 | 吴金凤 | Highly-oxidized sesquiterpene compound as well as preparation method and medical application thereof |
| CN105503995A (en) * | 2015-12-29 | 2016-04-20 | 吴金凤 | Novel triterpenoid compound as well as preparation method and medical application thereof |
| CN105503997A (en) * | 2015-12-30 | 2016-04-20 | 吴金凤 | Triterpenoid for treating salivary adenoid cystic carcinoma (SACC) and preparation method thereof |
| CN105503899A (en) * | 2016-01-25 | 2016-04-20 | 金华知产婺源信息技术有限公司 | Novel lignan compound and preparation method and medical application thereof |
| CN105541961A (en) * | 2016-03-04 | 2016-05-04 | 宋晓梅 | Withanolide compounds for treating adenoid cystic carcinoma of salivary gland |
Non-Patent Citations (2)
| Title |
|---|
| SOPHIA A. KOLESNIKOVA等: "Isolation, Structures, and Biological Activities of Triterpenoids from a Penares sp. Marine Sponge", 《JOURNAL OF NATURAL PRODUCTS》 * |
| 姜江: "甘草酸对涎腺腺样囊性癌SACC-M细胞系增殖和凋亡的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑，E057-305》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105294818A (en) * | 2015-12-07 | 2016-02-03 | 西宁意格知识产权咨询服务有限公司 | New triterpenoid as well as preparation method and medical application thereof |
| CN105541961A (en) * | 2016-03-04 | 2016-05-04 | 宋晓梅 | Withanolide compounds for treating adenoid cystic carcinoma of salivary gland |
| CN106008548A (en) * | 2016-06-02 | 2016-10-12 | 杭州更蓝生物科技有限公司 | New clerodane diterpenoid compound and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105061413A (en) | New limonin compound and pharmaceutical composition containing same, and preparation method and application thereof | |
| CN105111275A (en) | Novel triterpenes, and preparation method and medical application thereof | |
| CN105061548A (en) | Novel withanolides compound and preparation method and medical application thereof | |
| CN105330636A (en) | New flavonoid compound and preparation method and medical application thereof | |
| CN105418628A (en) | New kaurane diterpene compound as well as preparation method and application thereof | |
| CN105294817A (en) | Novel triterpenoid, preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105131013A (en) | Novel macrolide compound and preparation method and medical application thereof | |
| CN105198893A (en) | Diterpenoid compounds for treating stomach cancer | |
| CN105601695A (en) | Triterpenoid compound, preparation method and medical application in treatment of prostate cancer | |
| CN105503999A (en) | Limonin compounds for treating melanoma and preparation method thereof | |
| CN105175265A (en) | Novel diterpenoid compound for treating liver cancer | |
| CN105384750A (en) | Kauran diterpene compound for curing renal cancer | |
| CN105218617A (en) | A kind of new triterpenoid and preparation method thereof and medicinal use | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105566427A (en) | Lanostane triterpene compound, and preparation method and medicinal use thereof | |
| CN105294615A (en) | New limonin compound and preparation method and medicinal use thereof | |
| CN106074499A (en) | The application in medicine of a kind of Crow alkane type diterpene-kind compound | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105237380A (en) | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound | |
| CN105130935A (en) | New diterpenoid compounds for treating ovarian cancer | |
| CN105541961A (en) | Withanolide compounds for treating adenoid cystic carcinoma of salivary gland | |
| CN105273035B (en) | Compound and preparation method thereof | |
| CN105198844A (en) | Novel limonin compound as well as preparation method and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |
|
| RJ01 | Rejection of invention patent application after publication |